Table 4. Clinicopathological parameters vs. TRG hypermethylation frequency in primary tumors and histopathology(+) SLNs of pediatric cutaneous melanoma patients.
| Factors | Patients (n=37) |
RASSF1A(%) (n=37) |
RARβ2(%) (n=36*) |
APC(%) (n=36*) |
WIF1(%) (n=36*) |
|
|---|---|---|---|---|---|---|
| Gender* | ||||||
| Male | 20 | 6/20 (30) | 9/20 (45) | 4/19 (21.1) | 4/19 (21.1) | |
| Female | 17 | 6/20 (30) | 4/16 (25) | 4/17 (23.5) | 4/17 (23.5) | |
|
Age(years) (≤21)* |
||||||
| ≤ 18 | 18 | 5/18 (27.8) | 4/18 (22.2) | 4/17 (23.5) | 4/17 (23.5) | |
| > 18, ≤ 21 | 19 | 7/19 (36.8) | 9/18 (50) | 4/19 (21.1) | 4/19 (21.1) | |
|
Primary Site** |
||||||
| Extremities | 15 | 2/15 (13.3) | 5/14 (35.7) | 4/14 (28.6) | 3/15 (20) | |
| Head/Neck | 13 | 8/13 (61.5) | 5/13 (38.5) | 3/13 (23.1) | 2/13 (15.4) | |
| Trunk | 9 | 2/9 (22.2) | 3/9 (33.3) | 1/9 (11.1) | 3/8 (37.5) | |
|
Breslow Thickness* |
||||||
| <1.00mm | 9 | 3/9 (33.3) | 4/9 (44.4) | 3/9 (33.3) | 2/9 (22.2) | |
| 1.01-2.00mm | 9 | 3/9 (33.3) | 4/9 (44.4) | 1/9 (11.1) | 3/8 (37.5) | |
| 2.01-4.00mm | 11 | 5/11 (45.5) | 3/10 (30) | 3/10 (30) | 2/11 (18.2) | |
| >4.00mm | 8 | 1/8 (12.5) | 2/8 (25) | 1/8 (12.5) | 1/8 (12.5) | |
| Ulceration* | ||||||
| Present | 7 | 2/7 (28.6) | 2/7 (28.6) | 1/7 (14.3) | 2/7 (28.6) | |
| Absent | 27 | 9/27 (33.3) | 11/26 (42.3) | 6/26 (23.1) | 6/26 (23.1) | |
| Unknown | 3 | 1/3 (33.3) | 0/3 | 1/3 (33.3) | 0/3 | |
|
Mitotic Index* |
||||||
|
High ≥ 11/mm2 |
8 | 2/8 (25) | 2/8 (25) | 0/8 | 1/8 (12.5) | |
|
Intermediate 5-10/mm2 |
6 | 2/8 (25) | 3/8 (37.5) | 2/8 (25) | 1/8 (12.5) | |
| Low ≤ 4/mm2 | 22 | 8/22 (36.4) | 8/22 (36.4) | 6/22 (27.3) | 6/22 (27.3) | |
| Unknown | 1 | 0/1 | 0/1 | 0/1 | 0/1 |
*
NS
**
all NS except RASSF1A (p=0.018)